This suggests that inhibitors of the release and subsequent nuclear translocation of NF-κB, or the binding of NF-κB to DNA should be evaluated as potential agents to prevent muscle atrophy in cancer cachexia. The gene discussed is NFKB1; the disease is muscle atrophy.